Search Results

You are looking at 1 - 1 of 1 items for

  • Author: Anouk N A van der Horst-Schrivers x
Clear All Modify Search
Bernadette L Dekker Internal Medicine, Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

Search for other papers by Bernadette L Dekker in
Google Scholar
PubMed
Close
,
Anouk N A van der Horst-Schrivers Internal Medicine, Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
Department of Emergency Medicine, Maastricht University Medical Center, Maastricht, the Netherlands

Search for other papers by Anouk N A van der Horst-Schrivers in
Google Scholar
PubMed
Close
,
Adrienne H Brouwers Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

Search for other papers by Adrienne H Brouwers in
Google Scholar
PubMed
Close
,
Christopher M Shuford Laboratory Corporation of America Holdings, Center for Esoteric Testing, Burlington, North California, USA

Search for other papers by Christopher M Shuford in
Google Scholar
PubMed
Close
,
Ido P Kema Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

Search for other papers by Ido P Kema in
Google Scholar
PubMed
Close
,
Anneke C Muller Kobold Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

Search for other papers by Anneke C Muller Kobold in
Google Scholar
PubMed
Close
, and
Thera P Links Internal Medicine, Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

Search for other papers by Thera P Links in
Google Scholar
PubMed
Close

Objective

Thyroglobulin (Tg) is an established tumor marker for differentiated thyroid carcinoma (DTC) patients. However, Tg immunoassays can be subject to Tg autoantibody (TgAb) interference resulting in incorrect Tg values. Therefore, Tg measurement with liquid chromatography-tandem mass spectrometry (LC-MS/MS) could be promising in patients with TgAbs. In this study, we compared Tg IRMA and Tg-LC-MS/MS analytically in the presence of TgAbs. Furthermore, we compared the clinical interpretation of results obtained by both Tg assays in DTC patients with lower TgAbs titers (<10 U/mL) during 131I ablation therapy.

Methods

Totally 118 DTC patients diagnosed between 2006 and 2014 in a University Medical Center were followed with the Tg-IRMA (Thermo Fischer Scientific) and ARCHITECT anti-Tg (Abbott Laboratories) assays. We re-analyzed their samples with a sensitive Tg-LC-MS/MS method (Labcorp, limit of quantification of 0.02 ng/mL). Passing-Bablok regression analysis was performed on samples obtained during 131I ablation therapy and follow-up.

Results

In 304 samples with lower TgAb titers, a good analytical agreement was found between both Tg assays (slope of 1.09 (95% CI: 1.05–1.16)). Fifty-five samples with potentially interfering TgAbs showed higher Tg-LC-MS/MS values than Tg-IRMA (slope of 1.45 (95% CI: 1.12–>>100)). In patients(n  = 91) with lower TgAb titers at the time of 131I ablation therapy, the Tg assays showed a clinical concordance of 91.2, 87.9, and 98.9%, respectively, using a Tg cut-off value of 1.0, 2.0, and 5.0 ng/mL.

Conclusions

In DTC patients with lower titer TgAbs, Tg-IRMA is still a reliable and useful tumor marker. In DTC patients with potentially interfering TgAbs, Tg-IRMA values decreased due to TgAb interference.

Open access